Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy.
Mov Disord. 2023 Jul;38(7):1236-1252. doi: 10.1002/mds.29410. Epub 2023 May 5.
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.
To update LED conversion formulae based on a systematic review.
The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.
The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.
The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
为了比较帕金森病（PD）临床试验中的药物方案，已经开发出了抗帕金森药物之间的转换公式。这些公式是在 PD 药物治疗中以左旋多巴作为基准药物的“左旋多巴等效剂量”（LED）的基础上报告的。目前，基于系统评价，Tomlinson 等人于 2010 年提出的 LED 转换公式被广泛使用。然而，自 2010 年以来，已经开发出了具有既定和新颖作用机制的新药以及长期药物的新配方。因此，需要提出更新的 LED 转换公式的共识建议。
基于系统评价更新 LED 转换公式。
从 2010 年 1 月至 2021 年 7 月，检索 MEDLINE、CENTRAL 和 Embase 数据库。此外，根据 GRADE 网格方法的标准化流程，对缺乏左旋多巴剂量等效性数据的药物，提出了共识建议。
系统数据库搜索产生了 3076 篇文章，其中 682 篇符合纳入系统评价的标准。基于这些数据和标准化的共识过程，我们提出了目前可用于 PD 药物治疗或预计很快推出的各种药物的 LED 转换公式建议。
本立场文件中发布的 LED 转换公式将作为研究工具，用于比较 PD 研究队列中抗帕金森药物的等效性，并促进对药物和手术治疗以及其他非药物干预在 PD 中的临床疗效的研究。2023 年，作者。运动障碍由 Wiley Periodicals LLC 代表国际帕金森病和运动障碍协会出版。
